DuPont de Nemours recently released its 10-Q report for the quarter ended March 31, 2026. DuPont de Nemours, Inc. supplies technology-based materials and solutions across healthcare, water, construction, and industrial markets in the United States, Canada, Asia Pacific, Latin America, Europe, the Middle East, and Africa. The company operates through two segments, Healthcare & Water Technologies and Diversified Industrials, and sells products including TYVEK specialty materials, water filtration and separation systems, AMBERLITE ion exchange resins, FILMTEC reverse osmosis and nanofiltration elements, STYROFOAM insulation, CORIAN solid surface, Vespel shapes and parts, MOLYKOTE specialty lubricants, BETAFORCE and BETASEAL adhesives, and Cyrel flexographic printing plates.
In management’s discussion and analysis, DuPont said it had $2.0 billion of working capital and about $0.7 billion of cash and cash equivalents at March 31, 2026. The company said it expects cash on hand, cash from operations, and access to debt markets to cover liquidity needs. Two major portfolio moves shaped the period: the Electronics Business was separated on November 1, 2025, and the Aramids business was sold on April 1, 2026 for about $1.2 billion in pre-tax cash proceeds, plus a $300 million note receivable and a $325 million non-controlling equity interest.
DuPont reported first-quarter 2026 net sales of $1.681 billion, up 4% from $1.612 billion a year earlier. The increase reflected 2% organic growth and 2% favorable currency, with the weaker U.S. dollar versus the euro cited as the main currency driver. Cost of sales was $1.1 billion in both periods, while cost of sales as a percentage of net sales improved to 64% from 66%.
R&D spending was $47 million, down from $50 million. SG&A rose to $255 million from $234 million. Amortization of intangibles fell to $68 million from $75 million, and restructuring and asset-related charges increased to $46 million from $39 million, driven mainly by the 2026 DuPont Restructuring Program. Equity in losses of nonconsolidated affiliates narrowed to $1 million from $15 million, while sundry income declined to $36 million from $100 million and interest expense dropped to $40 million from $83 million. The effective tax rate on continuing operations was 17.1%, down from 17.5%.
Healthcare & Water Technologies posted first-quarter net sales of $806 million, up 6% from $763 million, and Operating EBITDA of $244 million, up from $223 million. Organic sales rose 3%, led by medical packaging and biopharma, while Water Technologies saw organic declines tied to logistics disruptions in the Middle East, partly offset by industrial water and microelectronics strength. Diversified Industrials reported net sales of $875 million, up 3% from $849 million, with Operating EBITDA of $200 million versus $185 million. Organic sales were flat, as gains in Industrial Technologies, including aerospace and automotive, were offset by weaker Building Technologies. Today the company's shares have moved 8.74% to a price of $49.3782. For the full picture, make sure to review DuPont de Nemours's 10-Q report.
